Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer

By Hirose Takashi   Shirai Takao   Ishida Hiroo   Ando Kohichi   Sugiyama Tomohide   Kusumoto Sojiro   Hosaka Takamichi   Nakashima Masanao   Ohmori Tohru   Adachi Mitsuru  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 267-274

Springer Publishing Company

Access to resources Recommend Favorite

Personalized peptide vaccination in patients with refractory non-small cell lung cancer

By                        

International Journal of Oncology, Vol. 40, Iss. 5, 2012-01 ,pp. : 1492-1500

Spandidos Publications

Access to resources Recommend Favorite

Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma - a multicentre phase I study

By Giannakakis T.   Ziras N.   Kakolyris S.   Mavroudis D.   Androulakis N.   Agelaki S.   Parashos M.   Sarra E.   Dimou T.   Hatzidaki D.   Vlachonikolis J.   Georgoulias V.  

European Journal of Cancer, Vol. 36, Iss. 6, 2000-04 ,pp. : 742-747

Elsevier

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Docetaxel (taxotere(R)) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

By Le Chevalier T.   Monnier A.   Douillard J.Y.   Ruffie P.   Sun X.S.   Belli L.   Ibrahim N.   Bougon N.   Berille J.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2032-2036

Elsevier

Access to resources Recommend Favorite